|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment strategies for advanced hepatocellular carcinoma:Sorafenib vs hepatic arterial infusion chemotherapy显示文摘Sorafenib is used worldwide as a first-line standardsystemic agent for advanced hepatocellular carcinoma(HCC) on the basis of the results of two large-scale Phase Ⅲ trials. Conversely,hepatic arterial infusion chemotherapy(HAIC) is one of the most recommended treatments in Japan. Although there have been no randomized controlled trials comparing sorafenib with HAIC,several retrospective analyses have shown no significant differences in survival between the two therapies. Outcomes are favorable for HCC patients exhibiting macroscopic vascular invasion when treated with HAIC rather than sorafenib,whereas in HCC patients exhibiting extrahepatic spread or resistance to transcatheter arterial chemoembolization,good outcomes are achieved by treatment with sorafenib rather than HAIC. Additionally,sorafenib is generally used to treat patients with Child-Pugh A,while HAIC is indicated for those with either Child-Pugh A or B. Based on these findings,we reviewed treatment strategies for advanced HCC. We propose that sorafenib might be used as a first-line treatment for advanced HCC patients without macroscopic vascular invasion or Child-Pugh A,while HAIC is recommended for those with macroscopic vascular invasion or Child-Pugh A or B. Additional research is required to determine the best second-line treatment for HAIC non-responders with Child-Pugh B through future clinical trials. | Issei Saeki Takahiro Yamasaki Masaki Maeda Takuro Hisanaga Takuya Iwamoto Koichi Fujisawa Toshihiko Matsumoto Isao Hidaka Yoshio Marumoto Tsuyoshi Ishikawa Naoki Yamamoto Yutaka Suehiro Taro Takami Isao Sakaida | 2018 | World Journal of Hepatology2018，10，9： | 10 |
| 2 | MUC5AC/β-catenin expression and KRAS gene alteration in laterally spreading colorectal tumors显示文摘AIM:To clarify differences in mucin phenotype, prolif-erative activity and oncogenetic alteration among subtypes of colorectal laterally spreading tumor (LST). METHODS:LSTs, defined as superficial elevated lesions greater than 10 mm in diameter with a low vertical axis, were macroscopically classified into two subtypes:(1) a granular type (Gr-LST) composed of superficially spreading aggregates of nodules forming a flat-based lesion with a granulonodular and uneven surface; and (2) a non-granular type (NGr-LST) with a flat smooth surface and an absence of granulonodular formation. A total of 69 LSTs, comprising 36 Gr-LSTs and 33 NGr-LSTs, were immunohistochemically stained with MUC2, MUC5AC,MUC6, CD10 (markers of gastrointestinal cell lineage), p53, β-catenin and Ki-67 antibodies, and examined for alteration in exon 1 of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and exon 15 of v-raf murine sarcoma viral oncogene homologue B1 (BRAF) by poly-merase chain reaction followed by direct sequencing. RESULTS:Histologically, 15 Gr-LST samples were adenomas with low-grade dysplasia (LGD), 12 were high-grade dysplasia (HGD) and 9 were adenocarcinomas invading the submucosa (INV), while 12 NGr-LSTs demonstrated LGD, 14 HGD and 7 INV. In the proximal colon, MUC5AC expression was significantly higher in the Gr-type than the NGr-type. MUC6 was expressed only in NGr-LST. MUC2 or CD10 did not differ. P53 expression demonstrated a significant stepwise increment in progression through LGD-HGD-INV with both types of LST. Nuclear β-catenin expression was significantly higher in the NGr-type. Ki-67 expression was signifi-cantly higher in the Gr-type in the lower one third zone of the tumor. In proximal, but not distal colon tumors, the incidence of KRAS provided mutation was signifi-cantly higher in the Gr-type harboring a specific mutational pattern (G12V). BRAF mutations (V600E) were detected only in two Gr-LSTs. CONCLUSION:The two subtypes of LST, especially in the proximal colon, have differing phenotypes of gastrointestinal cell lineage, proliferation and activation of Wnt/β-catenin or RAS/RAF/extracellular signal-regulated kinase signaling. | Kosaburo Nakae Hiroyuki Mitomi Tsuyoshi Saito Michiko Takahashi Takashi Morimoto Yasuhiro Hidaka Naoto Sakamoto Takashi Yao Sumio Watanabe | 2012 | World Journal of Gastroenterology2012，18，39： | 8 |
| 3 | Relationship between microvessel count and post-hepatectomy survival in patients with hepatocellular carcinoma显示文摘AIM: To elucidate the relationship between the microvessel count (MVC) by CD34 analyzed by immunohistochemical method and prognosis in hepatocellular carcinoma (HCC) patients who underwent hepatectomy based on our preliminary study. METHODS: We examined relationships between MVC and clinicopathological factors in 128 HCC patients. The modifi ed Japan Integrated Staging score (mJIS) was applied to examine subsets of HCC patients. RESULTS: Median MVC was 178/mm^2, which was used as a cut-off value. MVC was not signif icantly associated with any clinicopathologic factors or postoperative recurrent rate. Lower MVC was associated with poor disease-free and overall survivals by univariate analysis (P = 0.039 and P = 0.087, respectively) and lower MVC represented an independent poor prognostic factor in disease-free survival by Cox’s multivariateanalysis (risk ratio, 1.64; P = 0.024), in addition to tumor size, vascular invasion, macroscopic fi nding and hepatic dysfunction. Signifi cant differences in disease-free and overall survivals by MVC were observed in HCC patients with mJIS 2 (P = 0.046 and P = 0.0014, respectively), but not in those with other scores. CONCLUSION: Tumor MVC appears to offer a useful prognostic marker of HCC patient survival, particularly in HCC patients with mJIS 2. | Atsushi Nanashima Toshiyuki Nakayama Yorihisa Sumida Takafumi Abo Hiroaki Takeshita Kenichirou Shibata Shigekazu Hidaka Terumitsu Sawai Toru Yasutake Takeshi Nagayasu | 2008 | World Journal of Gastroenterology2008，14，31： | 7 |
| 4 | 血流介导的血管舒张,硝酸甘油诱导的血管舒张,基线肱动脉直径,充血剪切应力与心血管病危险因素之间的相关性显示文摘血流介导的血管舒张功能(flow-mediated vasodilation,FMD)已被用于评估内皮功能。充血性剪切应力(hyperemic shear stress,HSS,一种FMD的刺激因素)、硝酸甘油诱导的血管舒张(nitroglycerine-induced vasodilation,NID,非内皮依赖性血管舒张指数)以及基线肱动脉直径(brachial artery diameter,BAD)也参与血管舒张反应。 | 刘青 叶鹏 Maruhashi T Iwamoto Y Kajikawa M Oda N Kishimoto S Matsui S Hashimoto H Aibara Y Yusoff FM Hidaka T Kihara Y Chayama K Noma K Nakashima A Goto C Hida E Higashi Y | 2018 | 中华高血压杂志2018，26，1： | 5 |
| 5 | miR-218 on the genomic loss region of chromosome 4p15.31 functions asa tumor suppressor in bladder cancer显示文摘 | Shuichi Tatarano Takeshi Chiyomaru Kazumori Kawakami Hideki Enokida Hirofumi Yoshino Hideo Hidaka Takeshi Yamasaki Kazuya Kawahara Kenryu Nishiyama Naohiko Seki Masayuki Nakagawa | 2011 | International Journal of Oncology2011，，1： | 3 |
| 6 | Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma显示文摘AIM To evaluate the inhibitory effects of deferasirox(DFX) against hepatocellular carcinoma(HCC) through basic and clinical studies.METHODS In the basic study, the effect of DFX was investigated in three hepatoma cell lines(Hep G2, Hep3 B, and Huh7), as well as in an N-nitrosodiethylamine-induced murine HCC model. In the clinical study, six advanced HCC patients refractory to chemotherapy were enrolled. The initial dose of DFX was 10 mg/kg per day and was increased by 10 mg/kg per day every week, until the maximum dose of 30 mg/kg per day. The duration of a single course of DFX therapy was 28 consecutive days. In the event of dose-limiting toxicity(according to the Common Terminology Criteria for Adverse Events v.4.0), DFX dose was reduced.RESULTS Administration of DFX inhibited the proliferation of hepatoma cell lines and induced the activation of caspase-3 in a dose-dependent manner in vitro. In the murine model, DFX treatment significantly suppressed the development of liver tumors(P < 0.01), and significantly upregulated the mR NA expression levels of hepcidin(P < 0.05), transferrin receptor 1(P < 0.05), and hypoxia inducible factor-1α(P < 0.05) in both tumor and non-tumor tissues, compared with control mice. In the clinical study, anorexia and elevated serum creatinine were observed in four and all six patients, respectively. However, reduction in DFX dose led to decrease in serum creatinine levels in all patients. After the first course of DFX, one patient discontinued the therapy. We assessed the tumor response in the remaining five patients; one patient exhibited stable disease, while four patients exhibited progressive disease. The one-year survival rate of the six patients was 17%.CONCLUSION We demonstrated that DFX inhibited HCC in the basic study, but not in the clinical study due to dose-limiting toxicities. | Issei Saeki Naoki Yamamoto Takahiro Yamasaki Taro Takami Masaki Maeda Koichi Fujisawa Takuya Iwamoto Toshihiko Matsumoto Isao Hidaka Tsuyoshi Ishikawa Koichi Uchida Kenji Tani Isao Sakaida | 2016 | World Journal of Gastroenterology2016，22，40： | 3 |
| 7 | Selection of treatment modality for hepatocellular carcinoma according to the modified Japan Integrated Staging score显示文摘AIM: To compare the prognosis of patients who underwent hepatectomy and ablation using the modified Japan Integrated Staging score (mJIS).METHODS: We examined the clinicopathologic records and patient outcomes in 278 HCC patients including 226 undergoing hepatectomy and 52 undergoing ablation therapy.RESULTS: Cirrhosis was more frequent in the ablation group. Tumor size, number and presence of vascular invasion were significantly higher in the operation group compared to the ablation group. The local recurrence rate adjacent to treated lesions was significantly higher in the ablation group compared to the operation group (P < 0.05). The 3- and 5-year survival rates in the ablation and the operation group were 66% and 78%, and 50% and 63%, respectively, but not significantly different. Over 50% survival rates were observed in patients with a mJIS score of 0-2 in both groups. However, survival rates with a score of 3-5 in both groups were significantly lower.CONCLUSION: According to the mJIS system, both local treatments could be selected for patients with a score of 0-2. However, for patients with a score more than 3, liver transplantation might be a better option in patients with HCC. | Atsushi Nanashima Junichi Masuda Satoshi Miuma Yorihisa Sumida Takashi Nonaka Kenji Tanaka Shigekazu Hidaka Terumitsu Sawai Takeshi Nagayasu | 2008 | World Journal of Gastroenterology2008，14，1： | 2 |
| 8 | Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study显示文摘AIM To assess the effects of a combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients.METHODS A two-center,randomized,open-label,prospective study was conducted. Japanese patients who met the criteria were randomized to trial group and the combination diuretic group(received 7.5 mg of tolvaptan) or the conventional diuretic group(received 40 mg of furosemide) for 7 d in addition to the natriuretic drug which was used prior to enrolment in this study. The primary endpoint was the change in body weight from the baseline. Vital signs,fluid intake,and laboratory and urinary data were assessed to determine the pharmacological effects after administration of aquaretic and natriuretic drugs.RESULTS A total of 56 patients were randomized to receive either tolvaptan(n = 28) or furosemide(n = 28). In the combination and conventional diuretic groups,the average decrease in body weight from the baseline was 3.21 ± 3.17 kg(P < 0.0001) and 1.75 ± 2.36 kg(P = 0.0006),respectively,when measured on the final dosing day. Following 1 wk of treatment,a significantly greater reduction in body weight was observed in the combination diuretic group compared to that in the conventional diuretic group(P = 0.0412).CONCLUSION Compared to a conventional diuretic therapy with only a natriuretic drug,a combination diuretic therapy with natriuretic and aquaretic drugs is more effective for patients with cirrhotic ascites. | Haruki Uojima Hisashi Hidaka Tsuyoshi Nakayama Ji Hyun Sung Chikamasa Ichita Shinnosuke Tokoro Sakue Masuda Akiko Sasaki Kazuya Koizumi Hideto Egashira Makoto Kako | 2017 | World Journal of Gastroenterology2017，23，45： | 2 |
| 9 | miR-218 on the genomic loss region of chromosome 4p15.31 functions asa tumor suppressor in bladder cancer显示文摘 | Shuichi Tatarano Takeshi Chiyomaru Kazumori Kawakami Hideki Enokida Hirofumi Yoshino Hideo Hidaka Takeshi Yamasaki Kazuya Kawahara Kenryu Nishiyama Naohiko Seki Masayuki Nakagawa | 2011 | International Journal of Oncology2011，，1： | 2 |
| 10 | A role for IL-17 in induction of an inflammation at the fetomaternal interface in preterm labour显示文摘 | Mika Ito Akitoshi Nakashima Takao Hidaka Motonori Okabe Nguyen Duy Bac Shihomi Ina Satoshi Yoneda Arihiro Shiozaki Shigeki Sumi Koichi Tsuneyama Toshio Nikaido Shigeru Saito | 2009 | Journal of Reproductive Immunology2009，，1： | 2 |
| 11 | Development of biological filter as tertiary treatment for effective nitrogen removal: Biological filter for tertiary treatment显示文摘 | Jinwoo Jeong Taira Hidaka Hiroshi Tsuno Toshiyuki Oda | 2006 | Water Research2006，，6： | 2 |
| 12 | Tumor‐suppressive micro RNA ‐135a inhibits cancer cell proliferation by targeting the c‐ MYC oncogene in renal cell carcinoma显示文摘 | Yasutoshi Yamada Hideo Hidaka Naohiko Seki Hirofumi Yoshino Takeshi Yamasaki Toshihiko Itesako Masayuki Nakagawa Hideki Enokida | 2012 | Cancer Sci2012，，3： | 2 |
| 13 | Effect of bundles on nucleate boiling and critical heat transfer 显示文摘 | Fujita Y Hidaka S | 1998 | Heat Transfer Asian Research1998，27，4： | 2 |
| 14 | A fructo--oligosaccharides producing enzyme from Aspergillus niger ATCC20611 显示文摘 | HIDAKA H HIRAYAMA M SUMI N | 1988 | Agric Biol Chem1988，52，： | 1 |
| 15 | CTLA - 4 gene polymorphism associated with Graves 'disease in a Caucasian population 显示文摘 | Yanagawa T Hidaka Y Guimaraes V | 1995 | Clin Endocrinol Metab1995，80，1： | 1 |
| 16 | The haemodynamic effects of landiolol,anultra-short-actingβ1-selective bloker,onendotracheal intubation in patients with and without hypertension显示文摘 | Sugiura S Seki S Hidaka K | 2007 | Anesth Analg2007，104，1： | 1 |
| 17 | The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-显示文摘 | Sasaki Y Suzuki M Hidaka H | 2002 | Pharmacol Ther2002，93，： | 1 |
| 18 | Purification and properties of a fructo-oligosaccharide-producing fructofuranosidase from Aspergillus niger ATCC 20611显示文摘 | Hirayama M Sumi N Hidaka H | 1989 | Agric Biol Chem1989，53，3： | 1 |
| 19 | Heat tolerance in leaves of tropical fruit crops as measured by chlorophyll fluorescence显示文摘 | Yamada M Hidaka T Fukamachi H | 1996 | Sci Hort1996，67，： | 1 |
| 20 | Neoadjuvant intraarterial infusion chemotherapy in patients with stage I B2-ⅢBcervical Cancer显示文摘 | Yamakawa Y Fujimura M Hidaka T | 2000 | Gynecol Oncol2000，77，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员